DK4103566T3 - Kondenserede pyrimidinforbindelser som kcc2-modulatorer - Google Patents
Kondenserede pyrimidinforbindelser som kcc2-modulatorer Download PDFInfo
- Publication number
- DK4103566T3 DK4103566T3 DK21712145.8T DK21712145T DK4103566T3 DK 4103566 T3 DK4103566 T3 DK 4103566T3 DK 21712145 T DK21712145 T DK 21712145T DK 4103566 T3 DK4103566 T3 DK 4103566T3
- Authority
- DK
- Denmark
- Prior art keywords
- kcc2
- modulators
- pyrimidine compounds
- condensed pyrimidine
- condensed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062989104P | 2020-03-13 | 2020-03-13 | |
PCT/EP2021/056393 WO2021180952A1 (en) | 2020-03-13 | 2021-03-12 | Fused pyrimidine compounds as kcc2 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK4103566T3 true DK4103566T3 (da) | 2023-10-30 |
Family
ID=74874882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK21712145.8T DK4103566T3 (da) | 2020-03-13 | 2021-03-12 | Kondenserede pyrimidinforbindelser som kcc2-modulatorer |
Country Status (24)
Country | Link |
---|---|
US (1) | US20230151013A1 (da) |
EP (1) | EP4103566B1 (da) |
JP (1) | JP2023517680A (da) |
KR (1) | KR20220152319A (da) |
CN (1) | CN115298182A (da) |
AU (1) | AU2021234134A1 (da) |
BR (1) | BR112022018173A2 (da) |
CA (1) | CA3171192A1 (da) |
CL (1) | CL2022002386A1 (da) |
CO (1) | CO2022012884A2 (da) |
DK (1) | DK4103566T3 (da) |
ES (1) | ES2962136T3 (da) |
FI (1) | FI4103566T3 (da) |
HR (1) | HRP20231314T1 (da) |
HU (1) | HUE064037T2 (da) |
IL (1) | IL296265A (da) |
LT (1) | LT4103566T (da) |
MX (1) | MX2022011354A (da) |
PE (1) | PE20230106A1 (da) |
PL (1) | PL4103566T3 (da) |
PT (1) | PT4103566T (da) |
RS (1) | RS64823B1 (da) |
SI (1) | SI4103566T1 (da) |
WO (1) | WO2021180952A1 (da) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2024007009A (es) * | 2021-12-08 | 2024-08-22 | Kineta Inc | Heteroarenos bicíclicos y métodos para su uso. |
CN117843618A (zh) * | 2022-08-29 | 2024-04-09 | 北京沐华生物科技有限责任公司 | 一种ep300/cbp调节剂及其制备方法和用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090099195A1 (en) * | 2007-05-08 | 2009-04-16 | Astrazeneca Ab | Therapeutic Compounds 570 |
WO2015131080A1 (en) * | 2014-02-28 | 2015-09-03 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
US11331313B2 (en) * | 2017-05-22 | 2022-05-17 | Whitehead Institute For Biomedical Research | KCC2 expression enhancing compounds and uses thereof |
AU2019274481A1 (en) * | 2018-05-25 | 2020-12-03 | The Children's Medical Center Corporation | Methods for treating spinal cord injury |
-
2021
- 2021-03-12 LT LTEPPCT/EP2021/056393T patent/LT4103566T/lt unknown
- 2021-03-12 CN CN202180020856.3A patent/CN115298182A/zh active Pending
- 2021-03-12 EP EP21712145.8A patent/EP4103566B1/en active Active
- 2021-03-12 SI SI202130073T patent/SI4103566T1/sl unknown
- 2021-03-12 HR HRP20231314TT patent/HRP20231314T1/hr unknown
- 2021-03-12 JP JP2022554784A patent/JP2023517680A/ja active Pending
- 2021-03-12 ES ES21712145T patent/ES2962136T3/es active Active
- 2021-03-12 FI FIEP21712145.8T patent/FI4103566T3/fi active
- 2021-03-12 HU HUE21712145A patent/HUE064037T2/hu unknown
- 2021-03-12 PT PT217121458T patent/PT4103566T/pt unknown
- 2021-03-12 US US17/911,051 patent/US20230151013A1/en active Pending
- 2021-03-12 MX MX2022011354A patent/MX2022011354A/es unknown
- 2021-03-12 AU AU2021234134A patent/AU2021234134A1/en active Pending
- 2021-03-12 BR BR112022018173A patent/BR112022018173A2/pt unknown
- 2021-03-12 CA CA3171192A patent/CA3171192A1/en active Pending
- 2021-03-12 IL IL296265A patent/IL296265A/en unknown
- 2021-03-12 RS RS20231022A patent/RS64823B1/sr unknown
- 2021-03-12 PL PL21712145.8T patent/PL4103566T3/pl unknown
- 2021-03-12 WO PCT/EP2021/056393 patent/WO2021180952A1/en active Application Filing
- 2021-03-12 KR KR1020227035465A patent/KR20220152319A/ko active Search and Examination
- 2021-03-12 DK DK21712145.8T patent/DK4103566T3/da active
- 2021-03-12 PE PE2022001943A patent/PE20230106A1/es unknown
-
2022
- 2022-09-01 CL CL2022002386A patent/CL2022002386A1/es unknown
- 2022-09-09 CO CONC2022/0012884A patent/CO2022012884A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
FI4103566T3 (fi) | 2023-10-20 |
PT4103566T (pt) | 2023-11-09 |
WO2021180952A9 (en) | 2021-12-16 |
CL2022002386A1 (es) | 2023-04-28 |
SI4103566T1 (sl) | 2024-04-30 |
ES2962136T3 (es) | 2024-03-15 |
MX2022011354A (es) | 2022-11-30 |
CO2022012884A2 (es) | 2022-10-11 |
CN115298182A (zh) | 2022-11-04 |
US20230151013A1 (en) | 2023-05-18 |
EP4103566A1 (en) | 2022-12-21 |
CA3171192A1 (en) | 2021-09-16 |
EP4103566B1 (en) | 2023-10-04 |
RS64823B1 (sr) | 2023-12-29 |
PE20230106A1 (es) | 2023-01-25 |
KR20220152319A (ko) | 2022-11-15 |
HRP20231314T1 (hr) | 2024-02-16 |
AU2021234134A1 (en) | 2022-11-03 |
WO2021180952A1 (en) | 2021-09-16 |
JP2023517680A (ja) | 2023-04-26 |
IL296265A (en) | 2022-11-01 |
BR112022018173A2 (pt) | 2022-10-25 |
LT4103566T (lt) | 2023-11-10 |
HUE064037T2 (hu) | 2024-03-28 |
PL4103566T3 (pl) | 2024-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3774791T3 (da) | Heterocykliske forbindelser som immunmodulatorer | |
DK3873903T3 (da) | Substituerede 6-azabenzimidazolforbindelser som hpk1-hæmmere | |
DK3656769T3 (da) | Aryl-phosphor-oxygen-forbindelse som egfr-kinase-inhibitor | |
DK3697785T3 (da) | Imidazo-pyridine forbindelser som pad-inhibitorer | |
DK3577110T3 (da) | 8-oxetan-3-yl-3,8-diazabicyclo[3.2.1]octan-3-yl-substituerede forbindelser som hiv-inhibitorer | |
DK4081305T3 (da) | Diacylglycerinkinase modulerende forbindelser | |
DK3321265T3 (da) | 4,6-diamino-pyrido[3,2-d]pyrimidinforbindelser og deres udnyttelse som modulatorer af toll-lignende receptorer | |
DK3582780T3 (da) | Aminopyrimidinforbindelser, der er anvendelige som SSAO-inhibitorer | |
DK3294713T3 (da) | Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer | |
DK3684767T3 (da) | Heterocykliske forbindelser som pad-inhibitorer | |
DK3442980T3 (da) | Heterocykliske forbindelser som ret-kinase-hæmmere | |
DK3394033T3 (da) | Heterocykliske forbindelser som immunmodulatorer | |
DK3433253T3 (da) | Pyrimidinforbindelse som JAK-kinase-inhibitorer | |
DK3672965T3 (da) | Pyramidinforbindelse som Jak-kinase-inhibitor | |
DK3768674T3 (da) | Aminopyrimidinderivater som ctps1-hæmmere | |
DK3625228T3 (da) | Pyrimidinderivater som pge2-receptormodulatorer | |
DK3609898T3 (da) | Forbindelser, der er nyttige som ret-hæmmere | |
DK3303305T3 (da) | 2-(phenyloxy eller phenylthio)pyrimidin-derivater som herbicider | |
DK3333161T3 (da) | 2-(2,4,5-substitueret anilin)-pyrimidinderivater som egfr-modulatorer, der er anvendelige til behandling af cancer | |
DK3466934T3 (da) | Sulfonamidforbindelser eller salt deraf som ribonukleotidreductase-inhibitorer til behandling af kræft | |
DK3762368T3 (da) | Aminopyrazindiolforbindelser som pi3k-y-inhibitorer | |
DK3386991T3 (da) | Polycykliske forbindelser som inhibitorer af bruton's tyrosinkinase | |
DK3728207T3 (da) | Quinazolinoner som parp14-inhibitorer | |
DK3625222T3 (da) | Phenylderivater som pge2-receptormodulatorer | |
DK3552017T3 (da) | Forbindelser, der er anvendelige som ripk1-inhibitorer |